Tumor-associated macrophages: from mechanisms to therapy

By R. Noy, J. Pollard. Immunity, 2014

3,735 citations recorded by the source corpus.

The tumor microenvironment is a complex ecology of cells that evolves with and provides support to tumor cells during the transition to malignancy. Among the innate and adaptive immune cells recruited to the tumor site, macrophages are particularly abundant and are present at all stages of tumor progression. Clinical studies and experimental mouse models indicate these macrophages generally play a pro-tumoral role. In the primary tumor, macrophage can stimulate angiogenesis and enhance tumor cell invasion, motility and intravasation. During metastasis, macrophages prime the pre-metastatic site and promote tumor cell extravasation, survival and persistent growth. Macrophages are also immunosuppressive preventing tumor cell attack by natural killer and T cells during tumor progression and after recovery from chemo- or immuno-therapy. Therapeutic success in targeting these pro-tumoral roles in pre-clinical models and in early clinical trials suggests that macrophages are attractive targets as part of combination therapy in cancer treatment.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/6a7d64c6012ec52fd3c1f88d1ff28856ded291d0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Oncology

Citations in the corpus

Developmental and Functional Heterogeneity of Monocytes. (2018, background): “TAM exhibit negative activities on T cells and express high levels of programmed death ligand 1 (PD-L1), a ligand for immune-checkpoint receptor that restricts CD8 T cell activities (Noy and Pollard, 2014).”
Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis (2016, neutral): “…including the immunosuppressive microenvironment (e.g., myeloid-derived suppressor cells [Gabrilovich et al., 2012], tumor-associated macrophages [Noy and Pollard, 2014], FOXP3+ regulatory CD4+ T cells [Savage et al., 2013], IL-10, TGF-b, indoleamine-2,3 dioxygenase [IDO]), inhibitory checkpoint…”
Genetics and biology of prostate cancer (2018, background): “TAMs can be classified into tumor-suppressive M1 macrophages or tumor-promoting M2 macrophages (Biswas and Mantovani 2010; Noy and Pollard 2014), which can be distinguished by the differential expression of transcription factors and surface molecules as well as differences in their cytokine…”
Targeting Tumor Microenvironment for Cancer Therapy (2019, methodology): “The inhibition of CSF-1 signaling using anti-CSF-1R neutralizing antibodies or small molecule inhibitors has been used to decrease infiltration of TAMs and MDSCs and consequently inhibit tumor progression and metastasis [83,85].”
Roles of the immune system in cancer: from tumor initiation to metastatic progression (2018, background): “3; Noy and Pollard 2014; Kitamura et al. 2015; Gonzalez et al. 2018).”
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy (2017, background): “M2 macrophages/TAM have been reported to promote tumor growth, angiogenesis, invasion, and metastasis as well as resistance to therapy [3, 4].”
ANTIANGIOGENESIS STRATEGIES REVISITED: FROM STARVING TUMORS TO ALLEVIATING HYPOXIA (2014, neutral): “…(Casazza et al., 2014; Colegio et al., 2014; Finger and Giaccia, 2010; Hanahan and Coussens, 2012; Keith et al., 2012; Motz and Coukos, 2013; Noy and Pollard, 2014; Cancer Cell 26, November 10, 2014 ª2014 Elsevier Inc. 605 NS, not significant; NA, not available. aNo longer approved in the…”